NASDAQ: TECXTectonic Therapeutic Inc Stock
$17.02-0.54 (-3.08%)
Updated Apr 17, 2025
TECX Price
$17.02
Fair Value Price
N/A
Market Cap
$317.64M
52 Week Low
$13.70
52 Week High
$61.07
P/E
-2.49x
P/B
2.26x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$57.98M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$59M
Beta
1.19
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TECX Overview
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TECX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TECX
Ranked#184 of 463
Ranked#184 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important TECX news, forecast changes, insider trades & much more!
TECX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TECX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TECX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TECX is good value based on its book value relative to its share price (2.26x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
TECX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TECX due diligence checks available for Premium users.
Valuation
TECX fair value
Fair Value of TECX stock based on Discounted Cash Flow (DCF)
Price
$17.02
Fair Value
$6.58
Overvalued by
158.79%
TECX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TECX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.49x
Industry
-177.72x
Market
27.98x
TECX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.26x
Industry
4.05x
TECX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TECX's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.4M
Profit Margin
0%
TECX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$152.9M
Liabilities
$12.1M
Debt to equity
0.09
TECX's short-term assets ($146.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TECX's short-term assets ($146.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TECX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TECX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.8M
Investing
-$3.0k
Financing
-$1.1M
TECX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TECX vs Biotech Stocks
Tectonic Therapeutic Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.